Asia
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.
As the U.S. Food and Drug Administration begins to take aim at updating its 40-year-old draft guidance on drugs that treat major depressive disorder (MDD), three drugmakers with key business in that space are raising some concerns.
Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.
Swiss Pharma giant Roche expanded its presence in China with the approval of its lung cancer drug, Alecesna. Roche said the medication was approved by the China National Drug Administration under a priority review.
Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.
As investigations into China’s major vaccine scandals continue, a number of top regulators and politicians have been fired as a result. Bi Jingquan, former head of China’s Drug Administration, resigned. Two deputy Chinese provincial governors and one mayor were also fired by the Community Party over the scandal.
It’s been a while since FSH was manufactured using the urine of menopausal nuns. But now, an Israeli company, Bio-Technology General (BTG), owned by Italian company Ferring Pharmaceuticals, has developed a genetically-engineered version of FSH that can be personalized to improve the odds of a patient getting pregnant.
ALS is a progressive neurodegenerative disease that affects neurons in the brain and the spinal cord. The disease is usually fatal within two to five years of diagnosis. While there is no cure for the disease, multiple companies are working on treatments hoping to be the first to provide a viable option for patients like Scott Hayes. There are some treatments that may provide hope for patients.
Japan-based Astellas plunked down nearly $109 million to snap up privately-held gene therapy company Quethera Limited and its novel treatments for glaucoma and other ocular disorders.
CRISPR, the gene editing technique that promises designer babies, to end to all disease as we know it, and biohacking where individuals could change their own genome to include that of fluorescent jellyfish or lobster claws, seems to have more problems than originally thought.
PRESS RELEASES